Gapping up
News:
- TERN +34.4% (top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TERN-601)
- SMMT +30.8% (reports Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China)
- MGNX +7.1% (Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024)
- PL +6.2% (among companies selected for NASA award)
- BITF +5% (reschedules special meeting of shareholders; provides update on engagement with Riot)
- ZH +4.4% (commences tender offers to buy back up to $54.8 million of its class A ordinary shares and American Depositary Shares)
- IMVT +4.3% (Provides Update on Graves' Disease Development Program)
- NTRA +4.2% (to Present New Signatera Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival)
- SVRA +4.1% (New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024)
- RLAY +3.8% (Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival)
- RILY +3.7% (provides update on strategic and financing initiatives)
- NUVL +3.4% (provides Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles)
- RNAC +3.2% (Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis)
- VSTO +3.1% (issues comments on public communication from MNC Capital)
- OBE +2.4% (announces strong peace river results and upwardly revised guidance)
- TLRY +2.2% (Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms)
- SQSP +2% (Squarespace and Permira announced that they have agreed to amend their previously announced definitive agreement)
- ACB +1.8% (Aurora Cannabis and Vectura Fertin Pharma, Inc. announce launch of novel Luo CBD lozenge)
- BNL +1.4% (provides an update on recent business activity and announces participation at the Wells Fargo 13th Annual Net Lease REIT Forum)
- ZIM +1.4% (announces new operational cooperation with MSC covering the strategic transpacific trade)
- JOBY +1.3% (files for 3,320,235 shares of common stock offering by selling shareholder)